Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

Scientists reveal powerful role of astrocytes in the brain

A type of cell plentiful in the brain, long considered mainly the stuff that holds the brain together and oft-overlooked by scientists more interested in flashier cells known as neurons, wields more power in the brain than has been realized, according to new research published today in Science Signaling.

30 Mar 2012

Cardium commences Generx Phase 3 registration study in myocardial ischemia

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.

21 Mar 2012

UAB to present at annual American College of Cardiology Scientific Sessions

The University of Alabama at Birmingham has a number of presentations and experts available to comment on news being presented at the annual American College of Cardiology Scientific Sessions that begin Saturday, March 23, 2012, in Chicago.

20 Mar 2012

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

Aggrenox not affected by co-administration of omeprazole: Study

Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. These data were presented at the International Stroke Conference (ISC) in New Orleans.

3 Feb 2012

Novel nanosensors can lead to fewer experiments on animals

Countless mice, rats and rabbits die every year in the name of science - and the situation is getting worse. While German laboratories used some 2.41 million animals for scientific research in 2005, by 2009 this number had grown to 2.79 million. One third were destined for fundamental biology research, and the majority were used for researching diseases and developing medical compounds and devices.

11 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Patented ribose for food, beverage and supplement applications

Since 2008, the sales of ribose as an energy supplement increased by over 85%. This in conjunction with $9 billion sales of functional energy drinks in 2011 suggests that demand has never been higher for ingredients with a wide array of applications in functional food and beverage industries. Enter Bioenergy Ribose – the Superior Energy Ingredient.

31 Dec 2011

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Scientists identify A2bAR as possible new therapeutic target against atherosclerosis

Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol.

13 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

ArQule, Daiichi Sankyo enter license agreement for development of new AKT inhibitor

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors.

10 Nov 2011

Researchers discover new inherited disorder that causes mental retardation, liver dysfunction

Researchers at the Swedish medical university Karolinska Institutet have discovered a new inherited disorder that causes severe mental retardation and liver dysfunction. The disease, adenosine kinase deficiency, is caused by mutations in the ADK gene, which codes for the enzyme adenosine kinase.

1 Oct 2011

Acetyl-L-carnitine likely to improve outcomes and recovery for individuals with SCI

A commonly used supplement is likely to improve outcomes and recovery for individuals who sustain a spinal cord injury (SCI), according to research conducted by University of Kentucky neuroscientists.

29 Sep 2011

HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients

Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Cornell researchers learn how helicase enzyme works to unzip two strands of DNA

With an eye toward understanding DNA replication, Cornell researchers have learned how a helicase enzyme works to actually unzip the two strands of DNA.

19 Sep 2011